Scientists Mapped the Enzymes That Break Down a Key Brain Cannabinoid in Mice
One enzyme, MAGL, handles about 85% of the brain's 2-AG breakdown, with two lesser-known enzymes handling the rest in distinct brain locations.
Quick Facts
What This Study Found
Using proteomic techniques on mouse brain tissue, researchers identified three enzymes primarily responsible for breaking down 2-arachidonoylglycerol (2-AG), one of the brain's main endocannabinoids.
Monoacylglycerol lipase (MAGL) accounted for approximately 85% of total 2-AG hydrolysis in the brain. The remaining 15% was split between two previously uncharacterized enzymes called ABHD6 and ABHD12.
Notably, each of these three enzymes showed different subcellular distributions within neurons. This spatial separation suggests they may regulate distinct pools of 2-AG rather than serving redundant roles, potentially offering more precise targets for future drug development.
Key Numbers
MAGL accounted for approximately 85% of brain 2-AG hydrolase activity. ABHD6 and ABHD12 together accounted for most of the remaining 15%.
How They Did This
The researchers used activity-based protein profiling (ABPP), a functional proteomics approach, to identify and quantify all enzymes capable of hydrolyzing 2-AG in mouse brain homogenates. They used selective inhibitors to confirm the relative contributions of each enzyme and mapped their subcellular locations.
Why This Research Matters
Understanding which enzymes control 2-AG levels in the brain is essential for developing drugs that target the endocannabinoid system. Since 2-AG activates the same receptors that THC does, manipulating its breakdown could theoretically produce therapeutic effects without requiring external cannabinoids.
The Bigger Picture
This study laid important groundwork for understanding how the brain regulates its own cannabinoid signaling. The discovery that different enzymes control 2-AG in different cellular compartments opened new possibilities for developing more targeted medications that could modulate endocannabinoid tone with greater precision than broadly acting drugs.
What This Study Doesn't Tell Us
This was conducted entirely in mouse brain tissue, and enzyme distribution or relative activity could differ in human brains. The study examined brain tissue homogenates, which may not fully capture the dynamics of 2-AG metabolism in living, functioning neural circuits.
Questions This Raises
- ?Do ABHD6 and ABHD12 play clinically significant roles in human endocannabinoid regulation?
- ?Could selectively inhibiting one of these enzymes produce therapeutic effects with fewer side effects than inhibiting MAGL?
Trust & Context
- Key Stat:
- 85% of brain 2-AG breakdown handled by a single enzyme (MAGL)
- Evidence Grade:
- This is an animal study using advanced proteomic methods that provided quantitative data on enzyme contributions, but findings need human validation.
- Study Age:
- Published in 2007. Subsequent research has confirmed MAGL's dominant role and led to the development of selective MAGL inhibitors now in clinical testing.
- Original Title:
- A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol.
- Published In:
- Chemistry & biology, 14(12), 1347-56 (2007)
- Authors:
- Blankman, Jacqueline L(3), Simon, Gabriel M(2), Cravatt, Benjamin F(24)
- Database ID:
- RTHC-00264
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is 2-AG?
2-arachidonoylglycerol (2-AG) is one of two primary endocannabinoids produced naturally in the brain. It activates the same cannabinoid receptors (CB1 and CB2) that THC targets.
Why does it matter that different enzymes are in different locations?
If each enzyme controls 2-AG in a specific part of the cell, scientists could potentially target one enzyme to affect specific aspects of cannabinoid signaling without disrupting the entire system.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-00264APA
Blankman, Jacqueline L; Simon, Gabriel M; Cravatt, Benjamin F. (2007). A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol.. Chemistry & biology, 14(12), 1347-56.
MLA
Blankman, Jacqueline L, et al. "A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol.." Chemistry & biology, 2007.
RethinkTHC
RethinkTHC Research Database. "A comprehensive profile of brain enzymes that hydrolyze the ..." RTHC-00264. Retrieved from https://rethinkthc.com/research/blankman-2007-a-comprehensive-profile-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.